Robert Lisicki - 03 Jan 2022 Form 4 Insider Report for ARENA PHARMACEUTICALS INC

Role: EVP, Chief Commercial Officer
Signature: /s/ Andrew J. Cronauer, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 03 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2022, 16:00:19 UTC
Previous filing: 05 Aug 2021
Next filing: 11 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ARNA	Common Stock	Award	$0	+21,462	+133%	$0.000000	37,563	03 Jan 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.

Content

The amount represents restricted stock units that vest over four years, with 25% of the shares underlying the restricted stock units vesting on February 15, 2023, and the remainder vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), with such quarterly vesting dates occurring on the 15th of May, August, November, and February. The shares underlying the restricted stock units will be issued upon vesting and release of the restricted stock units.